The DOI matches its Crossref record; 56 of the 58 references it cites were found in a registry or an index, and 2 are not checked yet.
Rosiglitazone Monotherapy in Mild-to-Moderate Alzheimer’s Disease: Results from a Randomized, Double-Blind, Placebo-Controlled Phase III Study
Open accessAbstract
Background/Aims: A phase II study of the peroxisome proliferator-activated receptor-γ agonist rosiglitazone extended release (RSG XR) in mild-to-moderate Alzheimer’s disease (AD) detected a treatment benefit to cognition in apolipoprotein E(APOE)-Ε4-negative subjects. The current phase III study with prospective stratification by APOE genotype was conducted to confirm the efficacy and safety of RSG XR in mild-to-moderate AD. An open-label extension study assessed the long-term safety and tolerability of 8 mg RSG XR. Methods: This double-blind, randomized, placebo-controlled study enrolled 693 subjects. Within 2 APOE allelic strata (Ε4-positive, Ε4-negative), subjects were randomized (2:2:2:1) to once-daily placebo, 2 mg RSG XR, 8 mg RSG XR or 10 mg donepezil (control). Coprimary endpoints were change from baseline to week 24 in the Alzheimer’s Disease Assessment Scale-cognitive subscale (ADAS-Cog) score, and week 24 Clinician’s Interview-Based Impression of Change plus caregiver input (CIBIC+). Results: At week 24, no significant differences from placebo in change from baseline in coprimary endpoints were detected with either the RSG XR dose in APOE-Ε4-negative subjects or overall. For donepezil, no significant treatment difference was detected in ADAS-Cog; however, a significant difference was detected (p = 0.009) on the CIBIC+. Peripheral edema was the most common adverse event for 8 mg RSG XR (15%) and placebo (5%), and nasopharyngitis for 2 mg RSG XR (7%). Conclusion: No evidence of efficacy of 2 mg or 8 mg RSG XR monotherapy in cognition or global function was detected in the APOE-Ε4-negative or other analysis populations. The safety and tolerability of RSG XR was consistent with its known pharmacology.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, phase III clinical trials, using rosiglitazone, failed to show efficacy for the treatment of AD (Gold et al., 2010).”
From Mechanisms Underlying the Rapid Peroxisome Proliferator-Activated Receptor-γ-Mediated Amyloid Clearance and Reversal of Cognitive Deficits in a Murine Model of Alzheimer's Disease (2012) · cites this paper as Gold et al., 2010
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975) · Journal of Psychiatric Research · doi:10.1016/0022-3956(75)90026-6 · Cited by 88,282
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
EuroQol: a new facility for the measurement of health-related quality of life
(1990) · Health Policy · doi:10.1016/0168-8510(90)90421-9 · Cited by 15,736
The Neuropsychiatric Inventory: Comprehensive assessment of psychopathology in dementia
Cummings, J. L., Mega, M., Gray, K., Rosenberg-Thompson, S., Carusi, D. A., & Gornbein, J. (1994) · Neurology · doi:10.1212/wnl.44.12.2308 · Cited by 7,568
Román, G. C., Tatemichi, T. K., Erkinjuntti, T., Cummings, J. L., Masdeu, J. C., Garcia, J. H., Amaducci, L., Orgogozo, J.-M., Brun, A., Hofman, A., et al. (1993) · Neurology · doi:10.1212/wnl.43.2.250 · Cited by 4,921
A new rating scale for Alzheimer's disease
(1984) · American Journal of Psychiatry · doi:10.1176/ajp.141.11.1356 · Cited by 4,175
A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease
Rogers, S. L., Farlow, M. R., Doody, R. S., Mohs, R., Friedhoff, L. T., & Donepezil Study Group* (1998) · Neurology · doi:10.1212/wnl.50.1.136 · Cited by 1,618
Cummings, J. L. (2004) · New England Journal of Medicine · doi:10.1056/nejmra040223 · Cited by 1,152
Gélinas, I., Gauthier, L., McIntyre, M., & Gauthier, S. (1999) · American Journal of Occupational Therapy · doi:10.5014/ajot.53.5.471 · Cited by 918
Raskind (2000) · doi:10.1212/wnl.54.12.2261 · Cited by 870
Flagged first, then by citations
Cited by
Sorted by citations
Items 301–361 of 361
Alzheimer's Disease: Clinical Trials and Future Perspectives
Lee, K. S., & Suh, H. S. (2012) · 대한정신약물학회지 · Cited by 2
Xie, Z., Liu, Y., Huang, M., Zhong, S., & Lai, W. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e30909 · Cited by 3
PPARs (Peroxisome Proliferator-activated Receptors) and Their Agonists in Alzheimer's Disease
Kumar, M., Sharma, A. A., Datusalia, A. K., & Khatik, G. L. (2024) · Medicinal Chemistry · doi:10.2174/0115734064295063240422100615 · Cited by 3
Gopalakrishnan, M., & Gobburu, J. V. S. (2019) · Handbook of behavioral neuroscience · doi:10.1016/b978-0-12-803161-2.00018-7 · Cited by 3
Puerto, A. M. H., Russo, C., & Fregni, F. (2018) · Neuromethods · doi:10.1007/978-1-4939-7880-9_9 · Cited by 5
Mitochondrial Function and Neurodegenerative Diseases
Wilkins, H. M., Weidling, I., Koppel, S., Wang, X., von Schulze, A., & Swerdlow, R. H. (2018) · The Molecular and Cellular Basis of Neurodegenerative Diseases · doi:10.1016/b978-0-12-811304-2.00013-4 · Cited by 2
Cognitive Enhancers and Treatments for Alzheimer’s Disease
Devanand, D. P., & Fremont, R. (2023) · Springer eBooks · doi:10.1007/978-3-030-42825-9_139-1 · Cited by 3
Zhang, L., Wu, Y., Jin, Q., & Wang, C. (2025) · Journal of Alzheimer s Disease Reports · doi:10.1177/25424823251359579 · Cited by 2
Morelli, L., Perry, G. L., & Tagliavini, F. (2012) · International Journal of Alzheimer s Disease · doi:10.1155/2012/709613 · Cited by 2
Petersen, M. E., Gross, T. J., O’Bryant, S. E., & Mapstone, M. E. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-818845-3.00018-9 · Cited by 2
Drug Therapy of Alzheimer’s Disease: Cholinesterase Inhibitors, NMDA Antagonists
Nafees, S., Akram, M. F., & Khan, M. A. (2021) · Springer eBooks · doi:10.1007/978-981-16-4558-7_6 · Cited by 2
Alzheimer’s Disease: An Insightful Review on the Future Trends of the Effective Therapeutics
Hashmi, A., Srivastava, V., Kalam, S. A., & Mishra, D. K. (2022) · IntechOpen eBooks · doi:10.5772/intechopen.102762 · Cited by 2
Cognitive Enhancers and Treatments for Alzheimer’s Disease
Devanand, D. P., & Fremont, R. (2024) · Springer eBooks · doi:10.1007/978-3-030-51366-5_139 · Cited by 3
Drug Discovery from Medicinal Plants against Alzheimer's Disease
Marzouk, M. M., Farid, M. M., Hegazi, N. M., & Ezzat, S. M. (2023) · Wiley eBooks · doi:10.1002/9781119794127.ch3 · Cited by 4
Jiang, C., Qi, J., Zou, H., López, O. L., Xie, X., & Xue, Y. (2025) · Journal of Alzheimer s Disease · doi:10.1177/13872877251365662 · Cited by 1
Ghosh, A., Sarkar, S., Mandal, D., Orasugh, J. T., Ray, S. S., & Chattopadhyay, D. (2025) · Nano Trends · doi:10.1016/j.nwnano.2025.100144 · Cited by 2
Hu, D., Li, X., Li, Y., Zhang, Q., Dai, Y., Teng, X., Hou, H., & Li, J. (2025) · ChemBioChem · doi:10.1002/cbic.202500515 · Cited by 1
JAMDA: The Journal Continues to Have a High Impact
Morley, J. E. (2015) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2015.08.005 · Cited by 1
Geldmacher, D., Fritsch, T., & Landreth, G. E. (2011) · Archives of Neurology · doi:10.1001/archneurol.2011.58 · Cited by 1
Self-citationFatke, B., & Förstl, H. (2013) · Der Diabetologe · doi:10.1007/s11428-012-0951-9 · Cited by 2
Hurley, D. (2012) · Neurology Today · doi:10.1097/01.nt.0000410755.19813.06 · Cited by 1
Diabetes, Depression, and Cognitive Disorders
Holt, R. I. G. (2018) · Endocrinology · doi:10.1007/978-3-319-44433-8_24 · Cited by 1
Fatke, B., & Förstl, H. (2013) · Springer eBooks · doi:10.1007/978-3-642-29908-7_19 · Cited by 1
Modulation of BACE1 Activity as a Potential Therapeutic Strategy for Treating Alzheimer’s Disease
Klaver, D. W., & Tesco, G. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-803959-5.50009-x · Cited by 1
Diabetes, Depression, and Cognitive Disorders
Holt, R. I. G. (2018) · Endocrinology · doi:10.1007/978-3-319-27316-7_24-1 · Cited by 1
Diabetes, Depression, and Cognitive Disorders
Holt, R. I. G. (2020) · Endocrinology · doi:10.1007/978-3-030-36694-0_24 · Cited by 1
Potential Blood Biological Markers of Alzheimer's Disease
Metti, A. L. (2013) · D-Scholarship@Pitt (University of Pittsburgh)
Meðferðarúrræði við Alzheimerssjúkdómnum : lyf og lyfleysur
Árnadóttir, E. S. (2014)
Cognitive Enhancers and Treatments for Alzheimer's Disease
Devanand, D. P. (2015) · Wiley eBooks · doi:10.1002/9781118753378.ch109
The Janus Face of Insulin in Brain
Duarte, A. I., Candeias, E., Correia, S. C., Santos, R. X., Carvalho, C., Cardoso, S., Plácido, A. I., Santos, M. S., Oliveira, C. R., & Moreira, P. I. (2013) · Wiley eBooks · doi:10.1002/9781118395318.ch5
Downer, B. G. (2014) · UKnowledge (University of Kentucky)
Isotyping the Human TOMM40 Variable-Length Polymorphism by Gene Amplification and Restriction Digest
Greco, S. J., Hamzelou, A., Johnston, J. M., Richardson, S. L., Smith, M. A., Perry, G. L., Ashford, J. W., & Tezapsidis, N. (2012) · Current Alzheimer Research · doi:10.2174/156720512804142921
Efficacy of Anti-Diabetic Medicines in the Treatment of Alzheimer's Disease
Aajami, Z., & Nikfar, S. (2015) · DOAJ (DOAJ: Directory of Open Access Journals)
Population-based studies on the natural history of Alzheimer's disease and vascular dementia
Imfeld, P. (2012) · edoc (University of Basel) · doi:10.5451/unibas-006021310
Thomas, R. G., Albert, M., Petersen, R. C., & Aisen, P. S. S. (2016)
The Current Status of Alzheimer's Disease Treatment
Lanctôt, K. L., Kircanski, I., Chau, S. A., & Herrmann, N. (2012) · Frontiers in neuroscience · doi:10.1201/b11986-5
Gate, D., & Town, T. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-802851-3.00012-7
Potential Treatments for Alzheimer’s Disease
Farooqui, A. A. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-809937-7.00008-2 · Cited by 1
Diabetes, Depression, and Cognitive Disorders
Holt, R. I. G. (2019) · Endocrinology · doi:10.1007/978-3-319-27316-7_24-2
Faculty Opinions recommendation of Neuroinflammation in Alzheimer's disease.
Perani, D. (2017) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.725413893.793537457
Meta-Analysis of Natural vs Pharmaceutical Interventions for Alzheimer's Disease
Vrublevskaya, T. (2021) · San José State University ScholarWorks (San Jose State University) · doi:10.31979/etd.b494-dcd5
Mitochondria Are a Potential Therapeutic Target for Alzheimer’s Disease
Basavalingiah, A. J., Yan, S. F., & Yan, S. S. (2023) · Oxford University Press eBooks · doi:10.1093/oxfordhb/9780190932183.013.23
Yngrid Carneiro de Aguiar, I. S. D. O. A. A. O. B. (2023) · International Journal of Development Research · doi:10.37118/ijdr.27098.08.2023
Yadav, R., Mani, R. J., Kumar, A. H. S., Ahmad, S., & Katare, D. P. (2024) · Biomedical & Pharmacology Journal · doi:10.13005/bpj/2990 · Cited by 1
Review of drugs effective in Alzheimer's disease
Dawood, S. H., & Zavadsky, S. P. (2024) · Glavvrač (Chief Medical Officer) · doi:10.33920/med-03-2412-13
Catto, F., Dadgar‐Kiani, E., Kirschenbaum, D., Economides, A. E., Reuss, A. M., Trevisan, C., Caredio, D., Delic, M., Frick, L. D., Weber‐Stadlbauer, U., et al. (2025) · PLoS ONE · doi:10.1371/journal.pone.0309489
Metabolic connections between Alzheimer's disease and diabetes
Adhikary, K., Ganguly, K., Chowdhury, S. R., & Banerjee, P. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-33355-2.00024-4
Spector, S. A. (2013) · Elsevier eBooks · doi:10.1016/b978-0-12-411464-7.00021-3
Vieillissement cognitif réussi : système nerveux autonome, sommeil et interactions sociales
Martin, M. S. (2014) · theses.fr (ABES) · doi:10.70675/35437193z315bz403cza20dz5c3eb6890517
Vautheny, A. (2019) · theses.fr (ABES) · doi:10.70675/1812d71aze8d9z48d6z87d1z5a23a4e81953
Wu, Y., Di, Y., Wang, H. W., Wang, L., Zhang, J., Zhang, Y., & Lyu, D. (2026) · Ageing Research Reviews · doi:10.1016/j.arr.2026.103216
Neuroinflammation and Tauopathies
Zeenny, M.-N., Salame, I., Maatouk, L., & Akoury, E. (2026) · Molecular Biology Reports · doi:10.1007/s11033-026-12253-4
Mondal, A., Acharya, R., & Jain, S. (2026) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.6c00163
Shawaqfeh, B., Hughes, C. M., McGuinness, B., & Barry, H. E. (2026) · International Journal of Pharmacy Practice · doi:10.1093/ijpp/riag107
Sharma, N., & An, S. S. A. (2026) · Molecules · doi:10.3390/molecules31183274
Peroxisomes in Alzheimer’s disease: emerging mechanistic insights and therapeutic opportunities
Liu, T., Liu, Y., Zhang, Y., Wang, J., Ren, Y., Fu, S., Han, L., 蒋鹏成, Chen, J., Li, Y., et al. (2026) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2026.1960320
Ning, X., Xiao, Y., Wang, N., Jiao, X., Li, X., Zhang, Y., & Zhao, Q. (2026) · Journal of Alzheimer s Disease · doi:10.1177/13872877261491977
Gogu, M.-R., Costăchescu, I., Stanciu, G. D., Tamba, B.-I., Ciorpac, M., & Gorgan, L. (2026) · Pharmaceuticals · doi:10.3390/ph19101603
Maciel, V. C. B. D. O., Arruda, J. D. M., da Silva, R. C. T., & da Rosa, M. M. (2026) · Neurochemical Research · doi:10.1007/s11064-026-04908-2
BindingDB Entry 50018264: Targeting Nuclear Receptors in Neurodegeneration and Neuroinflammation.
BindingDB (2024) · UC San Diego · doi:10.7270/q27p93md
Metadata
- Authors
- Gold, M., Alderton, C., Zvartau-Hind, M., Egginton, S., Saunders, A. M., Irizarry, M., Craft, S., Landreth, G., Linnamägi, Ü., & Sawchak, S.
- Affiliations
- GlaxoSmithKline (United Kingdom) (GB)
- Duke University (US)
- University of Washington (US)
- Case Comprehensive Cancer Center (US)
- University of Tartu (EE)
- Venue
- Dementia and Geriatric Cognitive Disorders
- Publisher
- S. Karger AG
- Published
- 2010
- Volume
- 30
- Issue
- 2
- Pages
- 131-146
- ISSN
- 1420-8008 (ISSN-L)
- 1421-9824
- PMC
- PMC3214882
- OpenAlex
- W1978999542
- Cited by
- 361
- References
- 56
- Citations by year
- 2026: 12 · 2025: 17 · 2024: 20 · 2023: 21 · 2022: 23 · 2021: 25 · 2020: 26 · 2019: 22 · 2018: 22 · 2017: 19 · 2016: 22 · 2015: 24 · 2014: 24 · 2013: 25 · 2012: 31
- FWCI
- 18.20
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Dementia and Geriatric Cognitive Disorders (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- GlaxoSmithKline
- National Institute on Aging (R01AG030482)
- National Institute of Neurological Disorders and Stroke
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
- Keywords
- Alzheimer's disease, peroxisome proliferator-activated receptor gamma agonists, APOE ε4 genotype, donepezil, cognitive function, global function, peripheral edema, drug safety and tolerability, ADAS-Cog
- MeSH terms
- Rosiglitazone, Donepezil, Aged, Aged, 80 and over, Alleles, Alzheimer Disease, Apolipoproteins E, Cholinesterase Inhibitors, Edema, Female, Genotype, Humans, Hypoglycemic Agents, Indans, Intelligence Tests, Interview, Psychological, Male, Middle Aged, Nasopharyngitis, Piperidines, Treatment Outcome, Thiazolidinediones, PPAR gamma, Drug-Related Side Effects and Adverse Reactions
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
